FGFR4 Inhibitor Selectivity via Cys552 Targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current FGFR4 inhibitors lack selectivity and efficacy in targeting FGFR4 while sparing FGFR1-3, leading to potential toxicity and limited effectiveness in treating FGFR4-related cancers such as liver and renal cancer.
Innovation Solution
Development of a compound with a specific molecular structure featuring a fluorinated olefinic bond and dichloro substitution, which selectively inhibits FGFR4 kinases with enhanced activity and metabolic stability, allowing for effective treatment of FGFR4-related diseases without affecting FGFR1 kinases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If FGFR1-3 inhibitors are used, then FGFR1-3 activity is inhibited, but FGFR4 remains unaffected and potential toxicity occurs due to lack of selectivity
Solution Approach 1:
The patent applies local quality by introducing a specific cysteine residue at position 552 (Cys552) in the FGFR4 kinase domain, which creates a unique structural feature absent in FGFR1-3. This localized structural modification enables selective binding of the inhibitor to FGFR4 while sparing FGFR1-3, thereby achieving high selectivity and reducing off-target toxicity.
Solution Approach 2:
The invention exploits the asymmetric structural difference between FGFR4 and FGFR1-3 at the Cys552 position. The presence of cysteine at this specific location creates an asymmetric binding pocket that the inhibitor is designed to recognize, allowing differential inhibition of FGFR4 versus FGFR1-3 and eliminating the need for broad-spectrum FGFR inhibition.
2Reliability
If FGFR4 inhibitors are developed with high selectivity, then FGFR4-related cancers can be treated with reduced toxicity, but development complexity increases
Solution Approach 1:
The patent employs parameter changes by modifying the chemical structure of the inhibitor to include specific functional groups and molecular features that complement the Cys552 residue in FGFR4. By adjusting parameters such as molecular weight, hydrophobicity, and specific functional group positioning, the inhibitor achieves optimal binding affinity and selectivity for FGFR4 while maintaining manageable development complexity.
Data Source
AI summary
Provided are a class of compounds as shown in formula (I) as FGFR4 inhibitors, and pharmaceutically acceptable salts thereof, preparation methods therefor and the use thereof in the preparation of drugs for treating FGFR4-related diseases.